

CLAIMS

1. Use of a CD24 protein in the manufacture of a medicament for treating HIV-1/AIDS in a subject, wherein the CD24 protein comprises a mature human CD24 polypeptide.
2. The use of claim 1, wherein the mature human CD24 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 1 or 2.
3. The use of claim 2, wherein the CD24 protein further comprises a protein tag, wherein the protein tag is fused at the N-terminus or C-terminus of the CD24 protein.
4. The use of claim 3, wherein the protein tag comprises a Fc region of a mammalian immunoglobulin (Ig) protein.
5. The use of claim 4, wherein the Ig protein is human.
6. The use of claim 5, wherein the Fc region comprises a hinge region and CH2 and CH3 domains of IgG1, IgG2, IgG3, IgG4, or IgA.
7. The use of claim 5, wherein the Fc region comprises a hinge region and CH2, CH3 and CH4 domains of IgM.
8. The use of any one of claims 1-6, wherein the CD24 protein comprises the amino acid sequence set forth in SEQ ID NO: 6, 11, or 12.
9. The use of claim 8, wherein the amino acid sequence of the CD24 protein consists of the sequence set forth in SEQ ID NO: 6, 11, or 12.
10. The use of any one of claims 1-9, wherein the CD24 protein is produced using a eukaryotic protein expression system.
11. The use of claim 10, wherein the expression system comprises a vector contained in a Chinese Hamster Ovary cell line or a replication-defective retroviral vector.
12. The use of claim 11, wherein the replication-defective retroviral vector is stably integrated into the genome of a eukaryotic cell.
13. The use of any one of claims 1-12, wherein the CD24 protein is soluble.
14. The use of any one of claims 1-13, wherein the CD24 protein is glycosylated.